Publicacións en colaboración con investigadores/as de Universitat de València (7)

2024

  1. Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence

    Future Oncology, Vol. 20, Núm. 20, pp. 1401-1413

2022

  1. Correction to: SEOM‑GEMCAD‑TTD clinical guidelines for localized rectal cancer (2021) (Clinical and Translational Oncology, (2022), 24, 4, (646-657), 10.1007/s12094-022-02816-9)

    Clinical and Translational Oncology

  2. SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)

    Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 646-657

2016

  1. Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

    British Journal of Cancer, Vol. 114, Núm. 4, pp. 372-380

2012

  1. First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Onkologie, Vol. 6, Núm. 2, pp. 96-103

  2. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Oncologist, Vol. 17, Núm. 1, pp. 15-25

  3. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10